Research programme: mucosal-penetrating aciclovir - Kala Pharmaceuticals

Drug Profile

Research programme: mucosal-penetrating aciclovir - Kala Pharmaceuticals

Alternative Names: Aciclovir-MPP

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Kala Pharmaceuticals
  • Class Hypoxanthines
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpes simplex virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Prevention) in USA (Vaginal)
  • 13 Jul 2012 Preclinical trials in Herpes simplex virus infections prevention in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top